HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.

Slides:



Advertisements
Similar presentations
T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a–specific, HLA-DRB3*0101–restricted CD4+ T cells by Maria Therese.
Advertisements

Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell.
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.
A Promiscuous Survivin-Derived T-Cell Epitope Restricted to the HLA-A3 Super-Type Alleles  Niels Junker, Shamaila Munir, Pia Kvistborg, Per thor Straten,
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+precursors by Allan J. Masterson, Claudia C. Sombroek,
Expansion and isolation of NY-ESO-1–specific T cell clones.
Patient T cells recognise a SMAD4V370A-containing neoepitope presented by autologous cancer cells. Patient T cells recognise a SMAD4V370A-containing neoepitope.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
(A) NK cell cytotoxicity assays against K562, H9, and Raji target cell lines in the presence (black) and absence (white) of an anti-NKp30 antibody, clone.
Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia by Jochen Greiner, Yoko Ono, Susanne.
Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells by Martin R. Müller,
Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation 
Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.
The absence of ADCC by nivolumab in vitro.
HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients  Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,
Enhanced proliferation and cytokine production in DGKζ and Cbl-b deficient mice. Enhanced proliferation and cytokine production in DGKζ and Cbl-b deficient.
Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.
Volume 13, Issue 2, Pages (February 2006)
Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56  Rikke Bæk Sørensen,
Peanut T-cell epitope discovery: Ara h 1
Human PBMC-derived MERS-CoV–specific T cells are multifunctional.
Covering the Cover Gastroenterology
Mads Hald Andersen, Jürgen C. Becker, Per thor Straten 
DC subset cooperation for activation of antiviral T cells.
Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.
IFN-γ–producing cells in the spleen and lungs postimmunization.
PD-1 blockade enhances T-cell function.
Defining antigen-specific responses with human MHC class II tetramers
Lar function is not required for Stat92E accumulation in GSCs
Molecular Therapy - Oncolytics
CD8 T cell memory alters the immune profile in enhanced HLH without altering viral load. CD8 T cell memory alters the immune profile in enhanced HLH without.
MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. MR1Ts recognized by the hpMR1+EC tetramer are more likely to be TRAV1-2−. PBMCs.
Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity. Assessing the effect of TNF-α and TRAIL on A2-PPI15–24 CD8 T-cell cytotoxicity.
BMS blocks functional responses in primary immune cells driven by IFNα
M-MDSC:mast cell cross-talk in the regulation of TNFα production.
Specific recognition of HOM-MEL-40/SSX2-derived p pulsed targets by p stimulated T-cells from patients with HOM-MEL-40/SSX2 positive breast.
Natural processing and presentation of the HOM-MEL-40/SSX2-derived p peptide. Natural processing and presentation of the HOM-MEL-40/SSX2-derived.
Exosomes inhibit the nuclear translocation of NFAT and NFκB following activation. Exosomes inhibit the nuclear translocation of NFAT and NFκB following.
Specificity of HOM-MEL-40/SSX2 p stimulated CD8+ T-cells.
Evaluation of top candidate clones for selective killing in bispecific antibody format. Evaluation of top candidate clones for selective killing in bispecific.
CD91- and LOX-1-dependence of presentation of gp96-chaperoned peptides by MHC II. Presentation of gp96-chaperoned peptides by immature bone marrow-derived.
Cytotoxicity of p5399–107-induced CTL cells.
DCH-mediated cytotoxicity of isolated CD4+ and CD8+ T cells.
NY-ESO-1-specific cytotoxic reactivity of CD4+ T cell clones.
Flow cytometric analysis of single pMHCI-IgG binding and pMHCI delivery to hIGF-1R+ NIH3T3 and MCSP+ UCLA-SO-M14 cells target cells at different concentrations.
Direct recognition of MHC II/TARP14-27 on tumor cells by HTL
A2/Melan-A multimer+ CD8+ allorestricted CTL clones derived from donor DR fail to significantly recognize DR self-targets. A2/Melan-A multimer+ CD8+ allorestricted.
PBMC- and T cell-dependent cytotoxic activity of DCH and variant proteins. PBMC- and T cell-dependent cytotoxic activity of DCH and variant proteins. A.
Increased levels of inflammation in mo-DCs translate into higher numbers of specific CD8 T-cell responses. Increased levels of inflammation in mo-DCs translate.
OPN mediates maturation from immature DCs to mature DCs
Specific cytotoxicity of DTEGF13.
Specific inhibition of the Fab-HLA-A2/Flu induction of CTL mediated tumor cell lysis by a competing antibody. Specific inhibition of the Fab-HLA-A2/Flu.
Functional characterization of polyclonal Melan-A monospecific allorestricted CTLs. (A) Recognition of Melan-A peptides by the polyclonal Melan-A monospecific.
Cytofluorometry analysis demonstrating the specific coating of anti-tumor Fab-HLA-A2/Flu conjugates on the surface of HLA-A2 negative tumor target cells,
Cytotoxic activity of CD8+ T-cells stimulated with SSX2-derived p
Representative cytokine and cytotoxicity responses to CMV peptides on day 0 and day 7 in one HLA A2+ donor. Representative cytokine and cytotoxicity responses.
Frequency of misrepair studies with increasing concentrations of antibodies against NHEJ repair proteins. Frequency of misrepair studies with increasing.
Ligation efficiency is abrogated with increasing concentration of antibodies against NHEJ proteins. Ligation efficiency is abrogated with increasing concentration.
Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone. Characterizing an A*1101-restricted SSC-specific CD8+ cytotoxic T-cell clone.
Role of NO and IFNγ in mast cell–dependent MDSC-suppressive activities
LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.
Vaccination schedule. Vaccination schedule. Vaccinations were given in cycles; each cycle consisted of four injections (vertical lines). Up to four additional.
Induction of NY-ESO-1-specific CD4+ and CD8+ T cell responses after in vitro presensitization with NY-ESO-1 p or Ad2/ESO. Induction of NY-ESO-1-specific.
HLA restriction of spCD4 T-cell responses.
Location and modification of potential target peptides within PASD1.
Varying the MHC-I affinity, TCR affinity or antigen dose alters the phenotype of CD8 T cells ex vivo. Varying the MHC-I affinity, TCR affinity or antigen.
Design and operation of p.DOM-epitope vaccines.
Human monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived, HLA-A2-restriced epitope (NY-ESO-1157–165). Human.
Presentation transcript:

HLA-A*0201 restriction of SSX2-derived p103-111 stimulated CD8+ T-cells. HLA-A*0201 restriction of SSX2-derived p103-111 stimulated CD8+ T-cells. (A) COS7/A2 cells were loaded with decreasing concentrations of SSX2 p103-111 peptide (black) ranging from 2 to 0.002 µg/ml. For blocking, the anti-pan human MHC-I antibody (clone W6/32) (grey) or the anti-HLA-A*02 antibody (clone BB7.2) (white) was added. (B) To displace SSX2 p103-111, T2 cells were loaded with a mix of SSX2 p103-111 peptide (0.02 µg/ml) and increasing concentrations of the HLA-A*0201 binding, CMV-derived p495-503 peptide. Reactions were measured by IFN-gamma ELISPOT assay. Claudia Wagner et al. Cancer Immun 2003;3:18 Copyright © 2003 by Michael Pfreundschuh